Study of the effect of direct acting antivirals (DAAs) on fibrosis in chronic hepatitis C patients using transient elastography

Back ground: As DAA agents are leading to enormous cure rates, so identifying and monitoring patients who remain at a high complication risk after achieving SVR continue be critical issue. Numerous validated methods for noninvasive measurement of liver fibrosis can used in the management HCV infection. Methods study: A total 50 Egyptian chronic eligible treatment with DAAs were enrolled this prospective study. All subjects selected from Virology Unit Tropical Medicine Department, Faculty Medicine, Beni-Suef University received (SOV DCV) endpoint was sustained virologic response 12 (SVR12) weeks post-treatment. participants evaluated non-invasively by Liver Stiffness Measurement (LSM) Fibro Scan before treatment, 6 months Results: achieved therapy 96 % associated significant improvement (p ˂0.05) non-invasive markers (FIB-4, APRI score, LSM Scan) baseline compared Using fibro scan regression 30/45 (66%). inflammation synthetic functions also improved on follow up 12w 6m post treatment. Conclusion: Regression hepatitis C SOF DCV.